160 related articles for article (PubMed ID: 20431310)
1. [HER2 testing and targeted therapy in advanced gastric cancer].
Höhler T; Rüschoff J; Ridwelski K; Moehler M
Onkologie; 2010; 33 Suppl 4():26-30. PubMed ID: 20431310
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
[TBL] [Abstract][Full Text] [Related]
3. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.
Dai GH; Shi Y; Chen L; Lv YL; Zhong M
Hepatogastroenterology; 2012; 59(120):2439-44. PubMed ID: 22534547
[TBL] [Abstract][Full Text] [Related]
5. Targeted HER2 treatment in advanced gastric cancer.
Jørgensen JT
Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab in gastric cancer.
Okines AF; Cunningham D
Eur J Cancer; 2010 Jul; 46(11):1949-59. PubMed ID: 20542421
[TBL] [Abstract][Full Text] [Related]
7. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
8. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.
Koltz BR; Hicks DG; Whitney-Miller CL
Biotech Histochem; 2012 Jan; 87(1):40-5. PubMed ID: 21745161
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
10. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Bouché O; Penault-Llorca F
Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
[TBL] [Abstract][Full Text] [Related]
12. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
Marcom PK; Isaacs C; Harris L; Wong ZW; Kommarreddy A; Novielli N; Mann G; Tao Y; Ellis MJ
Breast Cancer Res Treat; 2007 Mar; 102(1):43-9. PubMed ID: 16897431
[TBL] [Abstract][Full Text] [Related]
13. Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review.
Kuo HY; Yeh KH
Anticancer Res; 2014 Jul; 34(7):3695-9. PubMed ID: 24982389
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
15. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
16. [Her2 testing in gastric cancer. What is different in comparison to breast cancer?].
Rüschoff J; Nagelmeier I; Baretton G; Dietel M; Höfler H; Schildhaus HU; Büttner R; Schlake W; Stoss O; Kreipe HH
Pathologe; 2010 May; 31(3):208-17. PubMed ID: 20443098
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma.
Safran H; Dipetrillo T; Akerman P; Ng T; Evans D; Steinhoff M; Benton D; Purviance J; Goldstein L; Tantravahi U; Kennedy T
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):405-9. PubMed ID: 17097832
[TBL] [Abstract][Full Text] [Related]
18. [HER2 and gastric cancer. Recommendations for clinical practice in 2011].
Penault-Llorca F; Chenard MP; Bouché O; Emile JF; Bibeau F; Metges JP; André T; Monges G
Ann Pathol; 2011 Apr; 31(2):78-87. PubMed ID: 21601111
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials of Herceptin(trastuzumab).
Baselga J
Eur J Cancer; 2001 Jan; 37 Suppl 1():S18-24. PubMed ID: 11167087
[TBL] [Abstract][Full Text] [Related]
20. HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis.
Negri FV; Bozzetti C; Ardizzoni A; Lagrasta C; Crafa P; Silini EM
Hum Pathol; 2011 Jun; 42(6):909-10; author reply 910-1. PubMed ID: 21571126
[No Abstract] [Full Text] [Related]
[Next] [New Search]